



Curriculum vitae Europass

Informații personale

Nume / Prenume

Volovat Simona Ruxandra

E-mail

simona-ruxandra.volovat@umfiasi.ro

Locul de muncă

Universitatea de Medicina si Farmacie "Grigore T Popa" Iasi;
Institutul Regional de Oncologie Iasi

Experiența profesională

Perioada

2024- prezent

Funcția sau postul ocupat

Conferentiar Universitar

Numele și adresa angajatorului

Universitatea de Medicina si Farmacie "Grigore T Popa" Iasi

Perioada

2022-2024

Funcția sau postul ocupat

Sef de lucrari

Numele și adresa angajatorului

Universitatea de Medicina si Farmacie "Grigore T Popa" Iasi

Perioada

2014-2024

Funcția sau postul ocupat

Asistent universitar

Numele și adresa angajatorului

Universitatea de Medicina si Farmacie "Grigore T Popa" Iasi

Perioada

2021-prezent

Funcția sau postul ocupat

Medic primar oncologie medicala

Numele și adresa angajatorului

Institutul Regional de Oncologie Iasi

Perioada

2015-2021

Funcția sau postul ocupat

Medic specialist oncologie medicala

Numele și adresa angajatorului

Institutul Regional de Oncologie Iasi

Perioada

2017-2018

Funcția sau postul ocupat

Medic specialist oncologie medicala

Numele și adresa angajatorului

Champalimaud Clinical Center- Breast Unit, Lisabona, Portugalia

Perioada

2011-2012

Funcția sau postul ocupat

Medic rezident oncologie medicala

Numele și adresa angajatorului

Institut Curie- Hopital Rene Huguenin, Paris, Franta

Perioada

2025- prezent

Funcția sau postul ocupat

Council member and Faculty member

Numele și adresa angajatorului

European School of Oncology

Educație și formare	
Perioada	2025- prezent
Calificarea / diploma obținută	testatul de abilitare, in domeniul de studii universitare de doctorat Medicină
Numele și tipul instituției de învățământ	Universitatea de Medicina si Farmacie "Grigore T Popa" Iasi
Perioada	2010-2015
Calificarea / diploma obținută	Doctor in stiinte medicale
Numele și tipul instituției de învățământ	Universitatea de Medicina si Farmacie "Grigore T Popa" Iasi
Perioada	2024-2025
Calificarea / diploma obținută	Molecular Ocology Master
Numele și tipul instituției de învățământ	Centro de Estudios Biosanitarios, Madrid, Spain
Perioada	2019-2020
Calificarea / diploma obținută	Global Clinical Scholars Research Training Program
Numele și tipul instituției de învățământ	Harvard Medical School, USA
Perioada	2019-2020
Calificarea / diploma obținută	Certificate of Competence in breast cancer
Numele și tipul instituției de învățământ	University of Ulm, European School of Oncology
Perioada	2022-2024
Calificarea / diploma obținută	Diploma de formare didactica
Numele și tipul instituției de învățământ	DPPD- Universitatea de Stiintele Vietii "Ion Ionescu de la Brad" Iasi

Aptitudini și competențe personale

Limba(i) străină(e)
cunoscută(e)

Autoevaluare
Nivel european ()*

Limba Engleza
Limba Franceza
Limba Portugheza
Limba Germana

Înțelegere				Vorbire				Scriere	
Ascultare		Citire		Participare la conversație		Discurs oral		Exprimare scrisă	
	C2		C2		C2		C2		C2
	C1		C1		C1		C1		C1
	C1		C1		C1		C1		C1
	B1		B1		B1		B1		B1

(*) Nivelul Cadruului European Comun de Referință Pentru Limbi Străine

Competențe și aptitudini organizatorice	- Coordonator departament oncologie medicala din cadrul UMF Iasi din 2025- prezent - Coordonator rezidenti oncologie medicala UMF Iasi- 2025- prezent
Competențe și aptitudini tehnice	Da
Competențe și aptitudini de utilizare a calculatorului	Windows, Microsoft Office, macOS, IBM SPSS, SAS, STATA
Competențe științifice	27 Capitole cărți 63 lucrări ISI (autor și coautor) 16 lucrări BDI (autor și coautor) 10 proiecte de cercetare (membru echipă proiect)
	Indice Hirsch = 18
	Factor cumulat de impact = 109,859

Data: 30.03.2026

Semnătura:

Anexa 1

Lista de articole

ARTICOLE ISI AUTOR PRINCIPAL

1. Volovat, S.R.; Augustin, I.G.; Volovat, C.; Vasilache, I.; Ostafe, M.; Panaite, D.I.; Burlacu, A.; Volovat, C.C. Rewriting Tumor Entry Rules: Microfluidic Polyplexes and Tumor-Penetrating Strategies—A Literature Review. *Pharmaceutics* 2026, 18, 84. **IF. = 5.5; Q1; Review**
2. Volovăț, S.R.; Panaite, D.I.; Ostafe, M.R.; Buzea, C.G.; Iancu, D.T.; Agop, M.; Ochiuz, L.; Rusu, D.I.; Volovăț, C.C. AI-Guided Inference of Morphodynamic Attractor-like States in Glioblastoma. *Diagnostics* 2026, 16, 139. **IF = 3.3; Q1, Article**
3. Volovat, C.C.; Cosovanu, M.A.; Ostafe, M.-R.; Augustin, I.G.; Volovat, C.; Georgescu, B.; Volovat, S.R. Bacteriophages, Antibiotics and Probiotics: Exploring the Microbial Battlefield of Colorectal Cancer. *Int.J. Mol. Sci.* 2025, 26, 7837. **IF = 4.9; Q1, Review**
4. Volovăț, C.C.; Buzea, C.G.; Boboc, D.-I.; Ostafe, M.-R.; Agop, M.; Ochiuz, L.; Burlea, Ș.L.; Rusu, D.I.; Bujor, L.; Iancu, D.T.; et al. Hybrid Deep Learning for Survival Prediction in Brain Metastases Using Multimodal MRI and Clinical Data. *Diagnostics* 2025, 15, 1242. **IF= 3.3; Q1, Review**
5. Volovăț, S.R.; Boboc, D.-I.; Ostafe, M.-R.; Buzea, C.G.; Agop, M.; Ochiuz, L.; Rusu, D.I.; Vasincu, D.; Ungureanu, M.I.; Volovăț, C.C. Utilizing Vision Transformers for Predicting Early Response of Brain Metastasis to Magnetic Resonance Imaging-Guided Stage Gamma Knife Radiosurgery Treatment. *Tomography* 2025, 11, 15. **IF = 2.2; Q2, Article**
6. Volovăț, S.R.; Popa, T.O.; Rusu, D.; Ochiuz, L.; Vasincu, D.; Agop, M.; Buzea, C.G.; Volovăț, C.C. Comparative Performance of Autoencoders and Traditional Machine Learning Algorithms in Clinical Data Analysis for Predicting Post-Staged GKRS Tumor Dynamics. *Diagnostics* 2024, 14, 2091 - **IF = 3.3, Q1, Article**
7. Ghizdovat, V., Dobreci, L., Slicaru, A., Cristuta, M., Dimitriu, D., Stefanescu, C., Vasincu, D., Ababei, R., Volovat, C., Agop, M., Eva, L., & Volovat, S. (2024). Analysis of Epileptic Seizures Stages through Attractor Dynamics. *BRAIN. Broad Research In Artificial Intelligence And Neuroscience*, 15(2), 159-174. **IF = 0.5, Q4, Article**
8. Nica I, Volovat C, Boboc D, Popa O, Ochiuz L, Vasincu D, Ghizdovat V, Agop M, Volovat CC, Ursulescu CL, Lungulescu CV, Volovat SR. A Holographic-Type Model in the Description of Polymer-Drug Delivery Processes, *Pharmaceutics*, 2024, 17(4): art. no 541. **IF=4.8, Q1, Article**
9. Volovăț, S.R.; Popa, T.O.; Rusu, D.; Ochiuz, L.; Vasincu, D.; Agop, M.; Buzea, C.G.; Volovăț, C.C. Comparative Performance of Autoencoders and Traditional Machine Learning Algorithms in Clinical Data Analysis for Predicting Post-Staged GKRS Tumor Dynamics. *Diagnostics* 2024, 14, 2091. **IF=3.3, Q1, Article**
10. Volovat CC, Scripcariu DV, Boboc D, Volovat SR, Vasilache IA, Ursulescu-Lupascu C, Gheorghe L, Baeen LM, Volovat C, Scripcariu V. Machine Learning-Based Algorithms for Enhanced Prediction of Local Recurrence and Metastasis in Low Rectal Adenocarcinoma Using Imaging, Surgical, and Pathological Data, *Diagnostics*, 2024, 14(6): art. no 625. **IF=3.3, Q1, Article**
11. Volovat CC, Scripcariu DV, Boboc D, Volovat SR, Vasilache IA, Lupascu-Ursulescu C, Gheorghe L, Baeen LM, Volovat C, Scripcariu V. Predicting the Feasibility of Curative Resection in Low Rectal Cancer: Insights from a Prospective Observational Study on Preoperative Magnetic Resonance Imaging Accuracy, *Med Lith*, 2024, 60(2): art. no 330. **IF=2.4, Q1, Article**
12. Volovat SR, Scripcariu DV, Vasilache IA, Stolniceanu CR, Volovat C, Augustin IG, Volovat CC, Ostafe MR, Andreea-Voichita SG, Bejusca-Vieriu T, Lungulescu CV, Sur D, Bobac D. Oncolytic Virotherapy: A New Paradigm in Cancer Immunotherapy, *Int J Mol Sci*, 2024, 25(2): art. no 1180. **IF=4.9, Q1, Review**
13. Andreica BI, Anisie A, Iftime MM, Ababei RV, Ochiuz L, Vasincu D, Vasilache IA, Volovat C, Boboc D, Poroach V, Eva L, Agop M, Scripcariu DV, Volovat SR. Theoretical-Experimental Approach of Chitosan/Quaternized Chitosan Nanofibers' Behavior in Wound Exudate Media, *Pharmaceutics*, 2023, 15(12): art. no 2722. **IF=4.9, Q1, Article**
14. Mirestean CC, Stan MC, Schenker M, Volovat C, Volovat SR, Iancu DTP, Iancu RI, Badulescu F. Immunotherapy with PD-1 Inhibitor Nivolumab in Recurrent/Metastatic Platinum Refractory Head and Neck Cancers-Early Experiences from Romania and Literature Review, *Diagnostics*, 2023, 13(16): art. no 2620. **IF=3, Q1, Review**

15. Haisan A, Hogas S, Mairean C, Punei MO, Volovat SR, Hogas M, Kantor C, Cimpoesu D. Compassion fatigue and compassion satisfaction among Romanian emergency medicine personnel, *Front Med*, 2023, 10: art. no 1189294. **IF=3.1, Q1, Article**
16. Himiniuc LM, Socolov R, Nica I, Agop M, Volovat C, Ochiuz L, Vasincu D, Rotundu AM, Rosu IA, Ghizdov V, Volovat SR. Theoretical and Experimental Aspects of Sodium Diclofenac Salt Release from Chitosan-Based Hydrogels and Possible Applications, *Gels*, 2023, 9(5): art. no 422. **IF=5, Q1, Article**
17. Iurciuc CE, Popa M, Atanase LI, Popa O, Ochiuz L, Postolache P, Ghizdov V, Irniciuc SA, Agop M, Volovat C, Volovat S. Multi-fractal modeling of curcumin release mechanism from polymeric nanomicelles, *Drug Deliv*, 2022, 29(1): 2883-2896. **IF=6, Q1, Article**
18. Volovat S, Apetrii M, Stefan A, Vlad C, Voroneanu L, Hogas M, Haisan A, Volovat C, Hogas S. Cisplatin and AKI: an ongoing battle with new perspectives-a narrative review, *Int Urol Nephrol*, 2023, 55(5): 1205-1209. **IF=1.8, Q3, Review**
19. Volovat SR, Augustin I, Zob D, Boboc D, Amurariti F, Volovat C, Stefanescu C, Stolniceanu CR, Ciocoiu M, Dumitras EA, Danciu M, Apostol DGC, Drug V, Al Shurbaji S, Coca LG, Leon F, Iftene A, Herghelegiu PC. Use of Personalized Biomarkers in Metastatic Colorectal Cancer and the Impact of AI, *Cancers*, 2022, 14(19): art. no 4834. **IF=5.2, Q2, Review**
20. Himiniuc LM, Toma BF, Popovici R, Grigore AM, Hamod A, Volovat C, Volovat S, Nica I, Vasincu D, Agop M, Tirnovanu M, Ochiuz L, Negura A, Grigore M. Update on the Use of Nanocarriers and Drug Delivery Systems and Future Directions in Cervical Cancer, *J Immunol Res*, 2022, 2022: art. no 1636908. **IF=4.1, Q2, Review**
21. Volovat SR, Ursulescu CL, Moisii LG, Volovat C, Boboc D, Scripcariu D, Amurariti F, Stefanescu C, Stolniceanu CR, Agop M, Lungulescu C, Volovat CC. The Landscape of Nanovectors for Modulation in Cancer Immunotherapy, *Pharmaceutics*, 2022, 14(2): art. no 397. **IF=5.4, Q1, Review**
22. Volovat SR, Negru S, Stolniceanu CR, Volovat C, Lungulescu C, Scripcariu D, Cobzeanu BM, Stefanescu C, Grigorescu C, Augustin I, Ursulescu CL, Volovat CC. Nanomedicine to modulate immunotherapy in cutaneous melanoma (Review), *Exp Ther Med*, 2021, 21(5): art. no 535. **IF=2.751, Q3, Review**
23. Volovat SR, Volovat C, Miron I, Kanbay M, Goldsmith D, Lungulescu C, Badarau SC, Covic A. Oncogenic mechanisms in renal insufficiency, *Clin Kidney J*, 2021, 14(2): 507-515. **IF=5.86, Q1, Review**
24. Lungulescu CV, Ungureanu BS, Turcu-Stolica A, Ghimpau V, Artene SA, Cazacu IM, Grecu AF, Dinescu VC, Croitoru A, Volovat SR. The role of IgE specific for galactose- α -1,3-galactose in predicting cetuximab induced hypersensitivity reaction: a systematic review and a diagnostic meta-analysis, *Sci Rep*, 2020, 10(1): art. no 21355. **IF=4.379, Q1, Article**
25. Volovat SR, Volovat C, Hordila I, Hordila DA, Mirestean CC, Miron OT, Lungulescu C, Scripcariu DV, Stolniceanu CR, Konsoulova-Kirova AA, Grigorescu C, Stefanescu C, Volovat CC, Augustin I. MiRNA and LncRNA as Potential Biomarkers in Triple-Negative Breast Cancer: A Review, *Front Oncol*, 2020, 10: art. no 526850. **IF=6.244, Q2, Review**
26. Agop M, Ghizdov V, Petrescu T, Oprea I, Paun MA, Paun VA, Paun VP, Volovat S. RELEASED DICLOFENAC SODIUM SALT FROM CHITOSAN EMBEDDING IN A HYDROGEL MATRIX. A THEORETICAL AND EXPERIMENTAL STUDY, *Univ Politeh Buchar Sci Bull-Ser A-Appl Math Phys*, 2020, 82(4): 201-212. **IF=0.903, Q4, Article**
27. Ghimpau V, Lungulescu C, Grecu AF, Gheonea DI, Danciulescu M, Gheorman V, Gheorman V, Volovat SR, Lungulescu CV. Correlations Between Distinct Ras Mutations and Response to Bevacizumab in Patients with Colo-rectal Cancer, *Rev Chim*, 2019, 70(6): 2222-2224. **IF=1.755, Q3, Article**
28. Ureche C, Tapoi L, Volovat S, Voroneanu L, Kanbay M, Covic A. Cardioprotective apelin effects and the cardiac-renal axis: review of existing science and potential therapeutic applications of synthetic and native regulated apelin, *J Hum Hypertens*, 2019, 33(6): 429-435. **IF=2.26, Q2, Review**
29. Cioca G, Pinteala M, Bacaita ES, Oprea I, Tanasa IC, Volovat SR, Dragan VS, Trocaru S, Anton C. Nonlinear Behaviors in Gene Therapy Theoretical and experimental aspects, *Mater Plast*, 2018, 55(3): 340-343. **IF=1.393, Q4, Article**
30. Volovat SR, Volovat CC, Miron L, Scripcariu DV, Semen ED, Ciocoiu M. Magnesium Supplementation and Cisplatin-Induced Renal Impairment in Cancer Patients, *Rev Chim*, 2018, 69(9): 2520-2523. **IF=1.605, Q3, Article**

31. Volovat SR, Volovat C, Negru SM, Danciu M, Scripcariu V. The efficacy and safety of hepatic arterial infusion of oxaliplatin plus intravenous irinotecan, leucovorin and fluorouracil in colorectal cancer with inoperable hepatic metastasis, *J Chemother*, 2016, 28(3): 235-241. **IF=1.577, Q3, Article**

ARTICOLE ISI COAUTOR

1. Median, M.D.; Antone, N.Z.; Volovăț, S.; Mazilu, L.; Negru, Ș.M.; Curcă, R.O.; Niță, A.; Pătru, R.I.; Ungureanu, A.; Lupu, V.; et al. Romanian Consensus Statement for Hormone Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer (HR+/HER2- mBC) and Triple-Negative Metastatic Breast Cancer (mTNBC). *Curr. Oncol.* 2026, 33, 120. **IF=3.4; Q2; Article**
2. Lungulescu, C.V.; Camen, G.-C.; Naidin, M.-S.; Berisha, T.-C.; Bită, A.; Dinescu, V.-C.; Buteica, S.A.; Dimulescu, M.-D.; Volovat, S.R.; Turcu-Stiolica, A. Real-World Efficacy and Adherence to Palbociclib in HR-Positive, HER2-Negative Advanced Breast Cancer: Insights from a Romanian Cohort. *Cancers* 2024, 16, 4161. **IF = 4.4; Q2, Article**
3. Anton SC, Lazan A, Grigore M, Ilea C, Scripcariu ȘI, Popa S, Volovăț S, Doroftei B, Nicolaiciuc D, Popovici D, Costăchescu G, Nicolaiciuc OS, Anton E. Current trends in breast cancer genetics, risk factors, and screening strategies. *J Biol Methods.* 2025 Mar 13;12(2):e99010054. - **IF =**
4. GBD 2023 Breast Cancer Collaborators, Sualeh Muhammad, J., & Tariq, S. (2026). Global, regional, and national burden of breast cancer among females, 1990–2023, with forecasts to 2050: a systematic analysis for the Global Burden of Disease Study 2023. *The Lancet Oncology*, 27(3), 302-326. **IF= 35.9; Q1, Article**
5. Global Burden of Cardiovascular Diseases and Risks 2023 Collaborators. Global, Regional, and National Burden of Cardiovascular Diseases and Risk Factors in 204 Countries and Territories, 1990–2023. *J Am Coll Cardiol.* 2025 Dec 2;86(22):2167-2243, **IF = 22.3; Q1, Article**
6. GBD 2021 Tobacco Forecasting Collaborators. Forecasting the effects of smoking prevalence scenarios on years of life lost and life expectancy from 2022 to 2050: a systematic analysis for the Global Burden of Disease Study 2021. *Lancet Public Health.* 2024 Oct;9(10):e729-e744. - **IF=25.2, Q1, Article**
7. GBD 2021 Stroke Risk Factor Collaborators. Global, regional, and national burden of stroke and its risk factors, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021. *Lancet Neurol.* 2024 Oct;23(10):973-1003. **IF= 45.5; Q1, Article**
8. GBD 2021 Risk Factors Collaborators. Global burden and strength of evidence for 88 risk factors in 204 countries and 811 subnational locations, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021, *Lancet*, 2024, 403(10440): 2162-2203. **IF=88.5, Q1, Article**
9. GBD 2021 Diseases and Injuries Collaborators. Global incidence, prevalence, years lived with disability (YLDs), disability-adjusted life-years (DALYs), and healthy life expectancy (HALE) for 371 diseases and injuries in 204 countries and territories and 811 subnational locations, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021, *Lancet*, 2024, 403(10440): 2133-2161. **IF=98.4, Q1, Article**
10. GBD 2021 Fertility and Forecasting Collaborators. Global fertility in 204 countries and territories, 1950–2021, with forecasts to 2100: a comprehensive demographic analysis for the Global Burden of Disease Study 2021, *Lancet*, 2024, 403(10440): 2057-2099. **IF=88.5, Q1, Article**
11. GBD 2021 Demographics Collaborators. Global age-sex-specific mortality, life expectancy, and population estimates in 204 countries and territories and 811 subnational locations, 1950–2021, and the impact of the COVID-19 pandemic: a comprehensive demographic analysis for the Global Burden of Disease Study 2021, *Lancet*, 2024, 403(10440): 1989-2056. **IF=88.5, Q1, Article**
12. GBD 2021 Nervous System Disorders Collaborators. Global, regional, and national burden of disorders affecting the nervous system, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021, *Lancet Neurol*, 2024, 23(4): 344-381 - **IF= 45.5; Q1, Article**
13. Gisca T, Munteanu IV, Vasilache IA, Melinte-Popescu AS, Volovat S, Scripcariu IS, Balan RA, Pavaleanu I, Socolov R, Carauleanu A, Vaduva C, Melinte-Popescu M, Adam AM, Adam G, Vicoveanu P, Socolov D. A Prospective Study on the Progression, Recurrence, and Regression of Cervical Lesions: Assessing Various Screening Approaches, *J Clin Med*, 2024, 13(5): art. no 1368. **IF=2.9; Q1, Article**
14. Turcu-Stiolica A, Udristoiu I, Subtirelu MS, Gheorman V, Aldea M, Dumitrescu EA, Volovat SR, Median DM, Lungulescu CV. Digging in real-word electronic database for assessing CDK 4/6

- inhibitors adherence in breast cancer patients from Romania, *Front Pharmacol*, 2024, 15: art. no 1345482. **IF=4.8, Q1, Article**
15. de Matos LV, Volovat S, Debiassi M, Cardoso F. Unfolding the role of the PI3K/AKT/MTOR pathway in male breast cancer: A pragmatic appraisal, *Breast*, 2023, 72: art. no 103576. **IF=5.7, Q1, Review**
 16. GBD 2019 Lip Oral Pharyngeal Canc. The Global, Regional, and National Burden of Adult Lip, Oral, and Pharyngeal Cancer in 204 Countries and Territories A Systematic Analysis for the Global Burden of Disease Study 2019, *JAMA Oncol*, 2023, 9(10): 1401-1416. **IF=22.5, Q1, Article**
 17. Ureche C, Dodi G, Covic A, Nedelcu A, Volovat S, Sascau RA, Statescu C, Covic A. Connection between Cardiac Fibrosis Biomarkers and Echocardiography Parameters in Advanced Chronic Kidney Disease Patients, *J Clin Med*, 2023, 12(8): art. no 3003. **IF=3, Q1, Article**
 18. Hinganu MV, Hinganu D, Palade OD, Eva I, Volovat SR, Cucu RP, Costan VV. Clinical and morphofunctional identity of the nasal SMAS, *Rom J Morphol Embryol*, 2023, 64(2): 199-206. **IF=1.2, Q4, Article**
 19. Sur D, Gorzo A, Sabarimurugan S, Krishnan SM, Lungulescu CV, Volovat SR, Burz C. A Comprehensive Review of the Use of Antioxidants and Natural Products in Cancer Patients Receiving Anticancer Therapy, *Anti-Cancer Agents Med Chem*, 2022, 22(8): 1511-1522. **IF=2.8, Q2, Review**
 20. Gorzo A, Galos D, Volovat SR, Lungulescu CV, Burz C, Sur D. Landscape of Immunotherapy Options for Colorectal Cancer: Current Knowledge and Future Perspectives beyond Immune Checkpoint Blockade, *Life-Basel*, 2022, 12(2): art. no 229. **IF=3.2, Q1, Article**
 21. Ghimpau V, Sur D, Volovat SR, Cazacu IM, Croitoru VM, Turcu-Stiolica A, Gheonea DI, Taerel AE, Subtirelu MS, Lungulescu CV. THE DIRECT COSTS BURDEN OF BEVACIZUMAB IN SOUTH-WEST ROMANIA, *Farmacia*, 2022, 70(1): 164-170. **IF=1.6, Q4, Article**
 22. Sur D, Lungulescu C, Puscariu II, Volovat SR, Preda M, Mateianu EA, Lungulescu CV. Immunotherapy-Related Publications in Colorectal Cancer: A Bibliometric Analysis, *Healthcare*, 2022, 10(1): art. no 75. **IF=2.8, Q2, Article**
 23. Stolniceanu CR, Moscalu M, Azoicai D, Tamba B, Volovat C, Grierosu I, Ionescu T, Jalloul W, Ghizdovot V, Gherasim R, Volovat S, Wang F, Fu JJ, Moscalu R, Matovic M, Stefanescu C. Improved Personalised Neuroendocrine Tumours' Diagnosis Predictive Power by New Receptor Somatostatin Image Processing Quantification, *J Pers Med*, 2021, 11(10): art. no 1042. **IF=3.508, Q2, Article**
 24. Lungulescu C, Croitoru VM, Volovat SR, Cazacu IM, Turcu-Stiolica A, Gheonea DI, Sur D, Lungulescu CV. An Insight into Deficient Mismatch Repair Colorectal Cancer Screening in a Romanian Population-A Bi-Institutional Pilot Study, *Med Lith*, 2021, 57(8): art. no 847. **IF=2.948, Q1, Article**
 25. Saftescu S, Negru E, Volovat S, Popovici D, Chercota V, Stanca S, Feier H, Malita D, Dragomir R, Volovat C. Predictors of the response to nivolumab immunotherapy in the second or subsequent lines for metastatic non-small cell lung cancers, *Exp Ther Med*, 2021, 21(6): art. no 605. **IF=2.751, Q3, Article**
 26. Saftescu S, Popovici D, Oprean C, Negru A, Haiduc A, Stanca S, Malita DC, Volovat S, Negru S. Determining factors of renal dysfunction during cisplatin chemotherapy, *Exp Ther Med*, 2021, 21(1): art. no 83. **IF=2.751, Q3, Article**
 27. Stolniceanu CR, Nistor I, Bilha SC, Constantin V, Simona V, Matovic M, Stefanescu C, Covic A. Nephrotoxicity/renal failure after therapy with Yttrium- and Lutetium - radiolabeled somatostatin analogs in different types of neuroendocrine tumors: a systematic review, *Nucl Med Commun*, 2020, 41(7): 601-617. **IF=1.69, Q3, Article**
 28. Ribnikar D, Volovat SR, Cardoso F. Targeting CDK4/6 pathways and beyond in breast cancer, *Breast*, 2019, 43: 8-17. **IF=3.754, Q1, Review**
 29. Nitescu DCK, Constantin M, Oanta C, Martu I, Volovat SR, Martu S. Evaluation of Cumulative Effects of Chemotherapy and Bevacizumab (Avastin) in Oncological Patients with Periodontal Disease, *Rev Chim*, 2017, 68(3): 549-552. **IF=1.412, Q3, Article**
 30. Axinte CI, Baciuc C, Volovat S, Tesloianu D, Borsos Z, Baciuc A, Agop M. FLOW DYNAMICS REGIMES VIA NON-DIFFERENTIABILITY IN COMPLEX FLUIDS, *Univ Politeh Buchar Sci Bull-Ser A-Appl Math Phys*, 2014, 76(2): 233-242. **IF=0.405, Q4, Article**
 31. Volovat C, Volovat SR, Scripcariu V, Miron L. SECOND-LINE CHEMOTHERAPY WITH GEMCITABINE AND OXALIPLATIN IN COMBINATION WITH LOCO-REGIONAL HYPERTHERMIA (EHY-2000) IN PATIENTS WITH REFRACTORY METASTATIC PANCREATIC CANCER - PRELIMINARY RESULTS OF A PROSPECTIVE TRIAL, *Rom Rep Phys*, 2014, 66(1): 166-174. **IF=1.517, Q2, Article**

32. Volovat C, Caruntu I, Costin C, Stefan A, Popa R, Volovat S, Siriopol D, Voroneanu L, Nistor I, Segall L, Covic A. Changes in the histological spectrum of glomerular diseases in the past 16 years in the North-Eastern region of Romania, BMC Nephrol, 2013, 14: art. no 148. **IF=1.52, Q2, Article**

Anexa 2

Vizibilitate internațională

- 1. Membru în comitetele științifice ale conferințelor internaționale/cu participare internațională**
 - Membru in comitetul stiintific al conferintei "Updates in Breast cancer Management" - aprilie 2025
- 2. Membru în board-urile asociațiilor profesionale internaționale**
 - Memebbru in consiliul Scolii europene de oncologie medicala (European School of Oncology)
- 3. Speaker/lector la Conferințe internaționale/cu participare internațională**
 - Speaker in cadrul National Cancer Conference BJCN-MORE 2024 Bulgaria,
 - International Meeting of Young Oncologist club Bulgaria 2023,
 - Multidisciplinarity & Personalized Medicine - A New Era in Oncology Bulgaria 2022;
 - Conferinta "Updates in Breast cancer Management" - 2025 Cluj Napoca,